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NEURAL EXPRESSION AND FUNCTION OF AUTISM CANDIDATE GENES IN 
ZEBRAFISH 
 
Elyse Ping Kite 
 
Thesis Chair: Brent Bill, Ph.D. 
 
The University of Texas at Tyler 
April 2017 
 
The Autism Spectrum Disorders (ASD) refer to a large heterogeneous set of 
developmental disorders defined by two behavioral domains: 1) Impairment of social 
comprehension and abnormal development of social communication, and 2) the presence 
of stereotypical and repetitive behaviors. The etiology of ASD is complex, with both 
genetic and environmental components. De novo and inherited mutations within DPP6 
and PSMD12 have been identified within individuals diagnosed with ASD suggesting an 
etiologic role. Understanding the functionality of these genes could lead novel treatments 
for ASD.  Zebrafish were utilized as a model system for the assessment of functionality 
of the orthologous genes dpp6a, dpp6b, and psmd12. Zebrafish are an ideal model system 
for neurological disorders because they develop quickly, share many fundamental brain 
structures and capacities with humans, and are genetically malleable. This work 
demonstrates commercially available antibodies designed to DPP6 bind promiscuously; 
therefore, necessitating a continued search for specific antibodies. In addition, three 
TALE Nucleases (TALENs) were designed to specifically target the psmd12 gene. In 
order to elucidate psmd12 mutants, genotyping assays were designed and a specific 
antibody was ascertained. These tools will be critical in the development of an allelic 
series and functional assessment of psmd12. 
 1 
 
 
 
Chapter 1: Introduction 
Autism  
!
Leo Kanner originally described autism in 19431; however, variability in 
presentation later led to the collation of several disorders such as Asperger’s Syndrome2, 
pervasive developmental disorder not otherwise specified3, Fragile X Syndrome4, and 
Rett Syndrome (RTT)5 under a much broader definition of the Autism Spectrum 
Disorders (ASD)6. The current diagnosis of ASD refers to a large heterogeneous set of 
developmental disorders defined by two behavioral domains: 1) Impairment of social 
comprehension and abnormal development of social communication, and 2) the presence 
of stereotypical and repetitive behaviors6.  
The prevalence of ASD is about 1% in North America, Asia and Europe7; 
however, recent studies conducted in South Korea and the United States note prevalences 
of 2.6%8  and 1.5%, respectively, of children born9. Complicating prevalence are 
differences between male and female occurrence. ASD is on average three times more 
common in males than females10. In those individuals classified as high functioning, 
presence of speech and lack of co-occurring intellectual delay, the male to female ration 
may be as high as 8:1, while in those classified as low functioning individuals the male to 
female ratio is closer to 1:111. It is not currently known if this is due to neurologic or 
genetic protection afforded by sex, or if traditional diagnostic tools that were developed 
using male behaviors are under diagnosing females with ASD. Changing diagnostic 
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metrics have been previously implicated in increased prevalence of ASD within the 
population, and may continue to impact epidemiologic numbers for this population12. 
The etiology of ASD is complex, with both genetic and environmental 
components. Twin studies demonstrated high concordance rates in monozygotic twins, 
with 50-90% trait heritability13-18, while it is only 0-30% heritable for dizygotic twins, 
comparable to the recurrence rate for non-twin siblings (3-26%)11,19. Recent studies have 
led to the definition of approximately 800 genetic loci linked to ASD based on the 
observation of recurrent chromosomal aberrations, common and rare copy number 
variants (CNVs), single nucleotide variations20-22, or differences in gene expression 
observed in the cortex of ASD post mortem brains23-29. While the identification of these 
genes has progressed rapidly, the characterization of their neurobiological function and 
role in ASD has lagged behind. This thesis will utilize the zebrafish (Danio rerio) to 
identify and accelerate the assignment of gene functionality of two new candidate genes, 
DPP6 and PSMD12. 
Zebrafish: A model organism for developmental disorders 
 
To look at functionality of ASD genes, Danio rerio (D. rerio) were utilized. D. 
rerio is an ideal model system for neurological disorders as they are small, robust, 
develop quickly, and share many fundamental brain structures and capacities with 
humans30. They produce up to 700, externally fertilized, eggs that generate transparent 
embryos per mating, that are genetically malleable31. There exist several well-developed 
transgenic and targeted gene knockdown (KD) or knockout (KO) methods for D. rerio; 
therefore, multi or single-gain-or-loss-of-function mutations can be efficiently generated 
to define gene interaction networks and novel regulatory connections32.  
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Morpholino oligonucleotides (MO) are used for temporary KD of protein 
function. MO were first introduced in 1996 as a method to inhibit the translation of RNA 
transcripts in vivo33, as they interfere with post-transcriptional RNA processing. They are 
injected into the yolks of developing one- to two-cell stage embryos. MO bind to a 
complementary sequence of their target mRNA resulting in inhibition of translation 
initiation. MO can also be designed to inhibit pre-mRNA splicing by preventing 
spliceosome formation. MO offer a quick transient KD of a protein, which may allow 
researchers to ascertain a phenotype allowing researchers to determine if a permanent KO 
is worth creating. There are, however, some disadvantages to MO. MO only provide a 
temporary inhibition of protein synthesis. As the embryo grows and develops the 
concentration of the injected MO will decrease and no longer effectively block translation 
of the protein of interest33,34. Injection of the MO also causes a set of characterized non-
specific effects due to the chemistry itself35. New genome engineering techniques, for 
example, Transcription Activator-Like Effector Nucleases (TALENs), have rapidly 
accelerated the process of site directed mutagenesis, reducing the initial barriers to 
permanent genome editing. Some researchers have proposed other techniques may 
replace MO entirely. 
Transcription Activator-Like (TAL) effectors were initially found in plant 
pathogen Xanthomonas spp36,37. TALs are proteins secreted by Xanthomonas spp will 
bind to specific nucleotides. The first TAL effector gene was discovered in 1989 during 
the cloning of a virulence protein Bs3 (avrBs3) by Bonas and colleagues38. TALENs are 
the fusion of a TAL effector DNA-binding domain and a FokI nuclease catalytic domain. 
The fusion of TAL and FokI allows for targeted DNA double-strand breaks in vivo. TAL 
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effectors can enter the nucleus, and bind to extremely specific sequences of DNA39 
(Figure 1). TALEN genome editing has been used successfully in zebrafish39 and 
livestock40.  
 
 
 
 
Figure 1. Schematic representation of a TALEN pair binding to its target sequence and 
cleaving double stranded DNA. Each TALEN is made of multiple TALEs at the amino 
acid terminus and a FokI nuclease at the carboxyl terminus. Each TALE repeat is 
comprised of 33-35 amino acids and recognizes a single base pair, called the repeat 
variable diresidue (RVD). 
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Just like with MO, TALENs are injected into one- to two-cell stage embryos; 
however, TALENs are targeted toward the nucleus of the cell instead of the middle of the 
yolk. Capped RNA encoding for the two TALENs is titrated and co-injected to optimize 
mutagenicity. Each TALEN complementarily binds its target sequence allowing for FokI 
nucleases to be brought within close enough proximity for cleavage. Subsequently, the 
nuclease causes a double-strand break at the target site. Imperfect repair by the error-
prone non-homologous end-joining (NHEJ) mechanism results in small insertions or 
deletions called indels. Indels that result in mutagenic frameshift changes or the 
introduction of an early stop codon are then selected to establish KO alleles. 
 
Dipeptidyl-Peptidase 6 
!
Dipeptidyl-Peptidase 6 (DPP6), also known as DPPX, was highlighted as an 
autism candidate gene after, de novo41 and inherited CNVs were found within the DPP6 
gene in individuals with ASD42-46. Mutations in DPP6 were observed in 5/2,588 autism 
cases and 1/2,690 neuro-typical controls. Four of the five cases were duplications in 
DPP6, while there was one case of DPP6 deletion47. In addition, Bock and colleagues 
identified a missense mutation in DPP6 that segregated with individuals with autistic 
phenotype in a multiplex family48. DPP6 is co-expressed with other autism candidate 
genes such as Astn2 (Astrotactin 2), Ptchd1 (Patched Domain Containing 1) and Galnt13 
(polypeptide N-acetylgalactosaminyltranserase 13)49.  
 In humans, DPP6 is expressed in muscle, heart, and neuronal tissue50,51. DPP6 is 
also expressed in mouse neuronal tissue, mouse facial tissue and monkey kidney (COS7 
cells)52-54.  Dpp6 expression has been investigated extensively in mice. Dpp6 mRNA is 
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expressed in several peripheral tissues in addition to the brain, such as ovary, prostate, 
testis and kidney. In the brain, DPP6 is expressed in the granule cell layers of the 
cerebellar cortex and in pyramidal neurons of the hippocampus55. Specific isoforms of 
DPP6 display unique patterns of expression. DPP6-L is exclusively expressed in the 
brain. While DPP6-S is expressed in olfactory regions and in high levels in hippocampal 
complex, DPP6-L has low expression in these regions56. DPP6-E is expressed in 
hippocampal pyramidal cell, cerebellar granule neurons and in neurons in the super 
colliculus55. DPP10, another autism candidate gene, which is closely related to DPP6 is 
expressed in the brain, pancreas, adrenal glands, spinal cord, Purkinje cells and 
GABAergic interneurons57,58.  
DPP6 is an auxiliary subunit of the voltage gated (Kv)-mediated A-type K+ 
channels that blocks ion flow following activation of the channel52. DPP6 is a type II 
membrane glycoprotein that has a single membrane-spanning domain, a large 
extracellular C-terminal domain, and a short alternately spliced intracellular N-terminal59. 
DPP6 plays an important role in Kv4.2 expression by promoting potassium channel 
trafficking to the dendrites50, and the loss of DPP6 can cause a decrease in the A-Type 
current, resulting in hyper-excitability of the dendritic tree by enhancing dendritic action 
potential back propagation, calcium electro-genesis and the induction of long-term 
synaptic potentiation60.  
Mouse models have been informative for function of this potassium channel 
regulator; however, a zebrafish model could provide a vehicle for high-throughput 
pharmaceutical screens or gene-gene interaction studies32. Zebrafish underwent a partial 
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genome duplication 300 million years ago, which resulted in two DPP6 orthologs, dpp6a 
and dpp6b61.  
 qRT-PCR and in situ hybridization have shown dpp6b expression as early as 2 
days post fertilization (dpf) and continuing through adult. In situ hybridization for dpp6b 
expression was observed within the zebrafish hypothalamus, optic tectum of the 
periventricular gray zone, thalamus, and torus longitudinalis. Immunohistochemistry 
(IHC) analysis utilizing a rabbit anti-DPP6 (abcam: ab41811) antibody, showed 
expression in brain areas similar to that of the in situ hybridization data mentioned above; 
however, broader staining in the cerebellum, fasciculus retroflexus, and several sensory-
associated neurons was also observed (unpublished data, Dr. Brent Bill) (Figure 2).  
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Figure 2. in situ hybridization dpp6b RNA expression demonstrates widespread neural 
expression and IHC with DPP6 antibody recognizes similar regions. (A) In, the torus 
longitudinalis, periventricular gray, and hypothalamus stains prominently, and confirms 
staining observed by IHC (B, C, and Figure E respectively). IHC was performed on 6-
micron sections of adult brain. Staining was observed in the (D) fasciculus retroflexus, 
(E) hypothalamus, and (G) optic nerve. 
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Proteasome 26S Subunit, Non-ATPase 12 
 
PSMD12 (Proteasome 26S Subunit, Non-ATPase 12), also known as Rpn5 or P55, 
is part of the non-ATPase subunits of the 26S proteasome. The proteasome was first 
discovered in 1977 by Etlinger and Goldberg62. The proteasome degrades misfolded, 
damaged, older or oxidized proteins63. It has multiple protease activities, and is capable 
of breaking down proteins into 7-8 amino acid long peptides. The targeting and 
degradation of proteins is characterized by two discrete steps: (1) conjugation of multiple 
ubiquitin moieties to a target protein in order to generate a polyubiquitin degradation 
signal, and (2) destruction of the targeted tagged protein by the 26S proteasome complex. 
 
Structure of 26S proteasome 
!
The 26S proteasome is a 2,000 kDa protein complex64 composed of two sub-
complexes, the 20S proteolytic core particle (20S-CP) and the 19S regulatory particle 
(19S-RP)65. The barreled shaped 20S-CP consists of four stacks of seven membered 
rings; the subunits are highly homologous. The proteasome contains an interior chamber, 
and the inner surface of this chamber promotes unfolding of proteins66. The proteolytic 
active sites are inside the 20S-CP barrel and access to these sites is regulated by a gated 
axial channel67-69. The 19S-RP is located at the ends of the 20S-CP. The 19S-RP is made 
up of at 19 subunits: 6 AAA-ATPase subunits (Rpt1-6) and 13 non-ATPase subunits: 
Rpn1-3, Rpn5-13, Rpn1570, and the DUB (deubiquitylating enzyme) Rpn1171. It is the 
job of theses subunits to recognize, unfold, and translocate the target protein into the core 
of the proteasome72,73. The 19S-RP can be broken down further into two subcomplexes: 
(1) the lid and (2) the base74,75. The base contains at least 10 subunits, six homologous 
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ATPases, two scaffold subunits Rpn1 and Rpn275 and two proteasomal Ub receptors 
Rpn1075,76 and Rpn1377. Rpn10 and Rpn13 are located on the apical part of the 26S 
proteasome78, and they recognize poly-ubiquityled substrates77,79. The six distinct 
regulatory particles known as AAA-ATPases: Rpt1-6 form a hexameric ring and 
constitute the molecular motor of the proteasome. PSMD12 resides in the lid of the 19S-
RP. The asymmetric lid subcomplex contains 7 other non-ATPase subunits: Rpn3, Rpn6-
9, Rpn11 and Rpn1274. Rpn11, also called PSMD14, is a metalloprotease that 
deubiquinates substrates preceding their degradation. The activity of PSMD14 is very 
important for efficient protein degradation80,81. PSMD14 activity can be regulated by 
PSMD1282. 
In 1997, Saito and colleagues cloned the p55 subunit of the human 26S 
proteasome and found that the disruption of their counterpart gene in yeast resulted in 
lethality. Yen and colleagues concluded the function of Rpn5, the homolog of PSMD12, 
is a highly conserved by rescuing the phenotype of a yeast rpn5Δ using human RPN5. 
Furthermore, they show Rpn5 potentially regulates assembly of the 26S proteasome in 
two different ways: 1) nuclear import and 2) assembly at the nuclear membrane83. In 
Arabidopsis thaliana there are two forms of RPN5 (RPN5a and RPN5b)36, and they are 
essential for the proper gametogenesis, sporophyte development and complex assembly. 
Homozygous rpn5a and rpn5b null mutants could not be generated. Single rpn5b mutants 
appeared wild-type, while single rpn5a mutants displayed many morphological defects. 
PSMD12 has gained further interest as it has been identified as the causative gene found 
with in a multiplex (multiple children with ASD family)84,85. Recently Küry reported 
reductions in optic tectum in zebrafish CRISPR/Cas9 mosaics. This suggests it is a 
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potential ASD susceptibility gene, as are other previously identified components of the 
ubiquitin proteasome system.  
 
The Ubiquitin Proteasome System (UPS) 
 
Functions of Ubiquitin modification 
 
Covalent modification of lysine residues with ubiquitin, ubiquitination, was 
discovered in the early 1980’s as a form post-translational modification84,86-89. It regulates 
many critical cellular functions including: modulation of the progression of the cell 
cycle90,91, DNA damage repair92, membrane protein maintenance93, apoptosis94,95, 
transcription regulation91, protein location96,  protein function97, protein degradation (see 
below), and facilitation of protein-protein interactions98. The best studied is the process of 
polyubiquitination, which marks proteins for degradation.  
In 2005, Avram Hershko, Aaron Ciechanover and Irwin A. Rose won the Nobel 
Prize in Chemistry for their description of the UPS99. In eukaryotes, the UPS is the major 
process regulating intracellular protein degradation100. The role of proteolysis is highly 
regulated in cells, it is crucial for cellular signaling, homeostasis and fate 
determination101-103. Proteins ligated with multiple ubiquitins are localized to the 26S 
proteasome for degradation.  
 Ubiquitin ‘labels’ target proteins in an energy-dependent, three-step pathway: (1) 
activation, (2) conjugation, and (3) ligation86. In the first step a high energy thioester 
linkage between Ub and E1 is formed when ubiquitin-activating enzyme (E1) binds to 
ATP, and Ub is transferred to a cysteine residue104. In the second step, conjugation occurs 
with a ubiquitin-conjugated enzyme (E2) that catalyzes the transfer of the activated Ub 
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from E1 to a cysteine residue on E2 via a trans(thio)esterification105. The final step is 
ligation that is catalyzed via ubiquitin-protein ligase (E3). An isopeptide bond is formed 
between the C-terminal glycine of Ub and a lysine residue in the target protein106. Within 
the human genome there are two E1 enzymes, at least 38 E2 enzymes, and thousands of 
E3 enzymes predicted107. The E3 ligases confer specificity for the final ubiquitination of 
the target protein108. There are three classes of E3 ligases as characterized by a conserved 
structural domain and by the mechanism by which Ub is transferred from the E2 to the 
target protein109.   
 
Neurons and the UPS 
 
The plasticity of brain circuits plays a large role in our ability to memorize and 
learn. Pharmacological inhibition of protein synthesis has been shown to impair behavior 
and synaptic plasticity. In order for the nervous system to effectively carry out tasks and 
function plastically proteins must be transcribed, modified and degraded. Therefore, 
regulation of protein synthesis and degradation are crucial for normal neuronal 
function110. 
The UPS has been shown to play a numerous roles in neuronal morphology and 
function111. Morphology is regulated by modifications of axonal growth and 
morphogenesis, dendritic outgrowth, and dendritic arborization. Neuronal function 
regulation is primarily mediated through regulation of neurotransmitter release through 
intracellular trafficking112-114, and protein homeostasis, availability and receptor function 
in synapses and mRNA translation110,115.  
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UPS enzymes have been observed in neurons, specifically near synapses and in 
the dendrites116-118, and associated or implicated in many diseases that involve the 
nervous system, such as: Alzheimer’s disease (AD), Parkinson’s disease (PD), dementia, 
and Huntington’s disease (HD)119. For many of these disorders, the mechanism of disease 
appears to be the inability for the UPS to target misfolded proteins, thus forming 
aggresomes that are toxic to the neurons and lead to cell death120,121. Supporting this 
hypothesis, overexpression of ubiquitin is capable of reducing protein aggregates and 
extending the lifespan of HD transgenetic mice122.  
 Angelman syndrome (AS) is a neurodevelopmental disorder whose main features 
are microcephaly, intellectual disability, seizures and lack of speech123. RTT is an X-
linked dominant disorder exclusive to females, which shows similar phenotypes as AS 
including microcephaly, cognitive impairment, seizures, and ataxia124. AS and RS  
(syndromic members of the ASD spectrum), and several non-syndromic autism spectrum 
disorders have been associated with the UPS124-126. The strongest association has been 
with the gene, UBE3A (Ubiquitin Protein Ligase E3A) that encodes for the HECT 
domain E3 protein127. UBE3A is located at 15q11-13128; this region is flanked by three 
low copy repeats leading to common recombination of this loci, and association with 
three neurodevelopmental disorders: autism, AS, and Prader-Willi Syndrome (PWS). A 
duplication or triplication of the maternally inherited 15q11-13 is one of the most 
common cytogentic events associated with autism126,129. De novo deletions of maternal 
15q11-q13 are responsible for about 70% of AS cases130,131; 5-10% of the cases are 
caused by mutations in the maternal 15q11-q13 region132; and 2-3% are caused by 
paternal uniparental disomy of chromosome 15133. Deletion of the paternal copy of the 
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15q11-q13 region leads to PWS129. Complete penetrance of autism is seen in individuals 
who have four copies of the gene and partial penetrance in those who have three 
copies129,134. In mice the loss of maternal UBE3A causes AS135,136 and the increase of 
UBE3A is associated with autism traits137,138. Therefore, based on the converging lines of 
evidence, the UPS could be a critical pathway in the etiology of ASD. 
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Chapter 2: Material and Methods 
 
Zebrafish maintenance 
Farm raised wild-type (WT) zebrafish were maintained, and used for experiments in 
accordance with terms and conditions of the University of Texas at Tyler standards 
(IACUC Protocol #112). The fish were kept on a 14-hour light/10-h dark cycle at 28°C in 
reverse osmosis (RO) purified water (pH 7.0) salted with Instant Ocean Sea Salt to a 
specific gravity of 1.004 (salinity 5.9). They were fed brine shrimp twice a day.  
 
Extraction of Zebrafish Protein 
Adult WT zebrafish or embryos were euthanized and tissue was harvested. The adult eyes 
and/or brains were stored on ice, and homogenized with 750ul of RIPA buffer 
(ThermoFisher, Cat#89901) and protease inhibitors (ThermoFisher Scientific, 
Cat#78441B). Lysates were then spun by centrifugation at 11,500 x g for 30 minutes at 
4°C to collect S1 fractions. Total protein concentration was determined by comparing 
protein extracts to a bovine serum albumin standard curve using the BCA assay kit 
(ThermoFisher Scientific, Cat#23225).  
 
Western Blotting 
Conventional Western blotting procedures were used to detect target proteins. Protein 
was loaded into pre-cast 7.5% SDS–PAGE gels (Biorad, Cat#456-1023). The gels were 
submerged in tris-glycine electrophoresis running buffer (Appendix C) and run for 60 
minutes at 175V. The proteins were transferred to a PVDF (polyvinylidene difluoride) 
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membrane (Millpore, Cat#IPVH00010) using a liquid transfer 280mA, run for 2 hours. 
Membranes were blocked in 5% milk block (Appendix C) for 2 hours or overnight. 
Membranes were probed with antibodies (Appendix A) and incubated overnight, 4°C in 
5% milk block. The membranes were washed three times in TBST, incubated with 
secondary antibodies (Appendix A) for 1 hour and washed three times in TBST 
(Appendix C). To visualize membranes NBT (1%) and BCIP (1.5%) substrate in alkaline 
phosphate (AP) buffer (Appendix C) were used. Band intensities were quantified with 
ImageJ software139. 
 
Immunohistochemistry (IHC) 
Embryos were collected at 2 and 3dpf, euthanized, and fixed with 4% paraformaldehyde 
(PFA) (Sigma, Cat#30525-89-4) overnight at 4ºC. Embryos were permeabilized four 
times for 5 minutes in phosphate-buffered saline (PBS) with 0.1% Triton-X (PBST) 
(Appendix C). The embryos were blocked in IHC blocking solution (Appendix C) for 2 
hours at room temperature. Subsequently, the embryos were incubated in rabbit anti-
DPP6 (ab41811) (1:500) or rabbit anti-PSMD12 (ab156604) (1:500) overnight at 4°C, 
washed in PBST three times, and incubated with secondary antibody goat anti-rabbit IgG 
Alexa Fluor® 546 (ThermoFisher, Cat#A-11010) at 4°C overnight. Embryos were 
mounted on slides and imaged with Carl Zeiss Axioskop 2 mot plus with a LSN 5 Pascal 
confocal attachment. 
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Bioinformatics 
DPP6: Sequences for human Dpp6 (Gene ID: 1804), zebrafish Dpp6a (Gene ID: 
00007104) and Dpp6b (Gene ID: 566832) were obtained from Genbank140, and aligned in 
Clustal Omega141 using default parameters. Synteny was established using a previously 
validated synteny database142 maps constructed with the source genome set as D. rerio 
with Homo sapiens (H. sapiens) as the outgroup.   
 
PSMD12: Protein sequences for Homo sapiens, Mus musculus, Gallus gallus, Xenopus 
laevis, Danio rerio, Drosophila melanogaster, and Saccharomyces. cerevisiae were 
identified through Unigene, and downloaded into the main CLC Workbench (https:// 
www.qiagenbioinformatics.com). Primers to verify expression and for genotyping were 
designed utilizing IDT Primerquest based on areas of high amino acid identity across all 
seven species examined.      
 
Bacterial strains, media and growth conditions 
All bacterial strains used were chemically competent. The strains used were: JM109 
(Promega, Cat#L2005), DH5⍺™ (ThermoFisher, Cat#18265017) and One Shot® 
Mach1™ T1 phage-resistant (ThermoFisher, Cat# C862003) cells were grown up 
following standard protocols. Liquid cultures were grown overnight in Luria broth (LB) 
(BD, Cat#244620) with appropriate antibiotics at 37°C, 225 rpm. Agar plates were made 
with LB+Agar (Appendix C) and appropriate antibiosis, if necessary.  
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Transformation procedures 
JM109 (Promega, Cat#L2005), DH5⍺™ (ThermoFisher, Cat#18265017) and One Shot® 
Mach1™ (ThermoFisher, Cat# C862003) bacterial cells were transformed according to 
provided standard protocols. 
 
Cloning of Psmd12 
RNA was harvested from WT zebrafish using Zymogen Direct-zol™ RNA MiniPrep Kit 
(Cat#R2050). RNA was used for first strand cDNA synthesis using both the oligod(T) 
and Random hexamer primers with the Promega GoScript™ Reverse Transcription 
System (Cat#A5000). The cDNA was amplified using gene specific primers (Appendix 
B) and Promega Go Taq PCR kit (Cat#M7805). 
 
The full-length zebrafish psmd12 sequence was ligated into Promega pGEM®-T vector 
(Cat#A362A) and transformed into JM109 (Promega, Cat#L2004) following the Promega 
pGEM® Vector Systems instructions manual (Cat#A1360). Bacteria were grown on 
Luria-Bertani + ampicillin (100ug/ml) agar plates, colonies were selected, purified using 
Qiagen MiniPrep Kit (Cat# 27106) and sequenced by Eurofins SimpleSeq 
(http://www.eurofinsgenomics.com/).  
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Morpholino oligonucleotides (MO) 
Morpholino Design  
Three different 24 base pair (bp) MO were designed. Two 24 base pair (bp) sequences 
were identified at the 1st exon and one at the 3rd exon. The splice acceptor (PSMD12 
E3SA) was created against exon 3 and the two translational blocker MO were designed 
against exon 1: start of translation (PSMD12 ATG), or 14 bp upstream of the 
translational start (PSMD12 5p). All MO designed did not show the ability to form 
hairpins, and were unique to psmd12 (next nearest blast hit was 15/15 bp match). They 
also had a GC of ~50% without four guanines in a row. A negative control MO 
(PSMD12 ATG MS) was designed; it differs from the translational start morpholino 
(PSMD12 ATG) by 5 bp. The MO constructs will sterically hinder the production of 
PSMD12 RNA in zebrafish in order for us to observe phenotype changes in the nervous 
system (See Appendix B for MO primer table). 
Designed MO:  
1.! PSMD12 ATG: Translational blocker. Starts 14 bp in front of the PSMD12 start 
codon and covers 10 bp in to the start codon The ATG and PSMD12 5p MO will 
block the binding of the small ribosomal subunit.  
2.! PSMD12 5p: Translational blocker, further upstream 5’UTR.  
3.! PSMD12 ATG Mismatch (MS): Negative control that is identical to the PSMD12 
ATG MO, except for a 5 bp mismatch difference. Therefore, it will not bind to the 
mRNA.  
4.! PSMD12 E3SA: Splicesome blocker. 100% complementary to 17 bp in PSMD12 
exon 3. This MO blocks the splicesome from cleaving exon 3. 
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Morpholino Injection 
Injections were done following the methods described in Bill and colleagues35. We 
injected with and without the tP53 MO to account for background phenotypes due to the 
upregulation of the P53 pathway. Efficiency of injection was determined using a positive 
control chordin:fluorescein MO.  
 
TALEN Creation 
GoldyTALENs Design 
TALENs were designed using Mojo Hand software143. Highly conserved areas of the 
genome were targeted using CLC Workbench and the specificity of primers confirmed 
using NCBI Primer-BLAST (http://blast.ncbi.nlm.nih.gov/Blast.cgi). Three sites were 
targeted: PSMD12E3 site 1, PSMD12E3 site 127 and PSMD12E6 site 11. Two primers 
were designed for each site surrounding the targeted loci by approximately 1000 bp 
(Figure 9 and 10). RFLP’s within these amplicons are the basis for genotyping assays. 
The TALEN targeting sequences are shown below. Targeting sequences were validated 
by reverse transcriptase PCR of WT zebrafish RNA, and we demonstrated a lack of 
polymorphisms or sequencing errors for each site. 
 
Specific TALEN RVDs and Restriction Enzymes: 
PSMD12E3 site 1: Exon 3 
TAL1: NG HD NN NN NI NG NI NG NN NN NG NN NG HD NG 
TAL2: NI NI HD NG NN NI NI HD NG NI NG NG NN HD HD NI HD 
Restriction enzyme: AlwI (www.neb.com/R0513) 
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PSMD12E3 site 127: Exon 3 
TAL-1: HD NG NN NI NI HD NN NI NI NI NI HD NI NG HD NI 
TAL-2: NN HD NG NG HD NI NN HD NG NN NN HD NG NG HD NG NG 
Restriction enzyme: BbvI (www.neb.com/R0173) 
 
PSMD12E6 site 11: Exon 6 
TAL-1: NN NN NI NN NI NI NN NI NI NI NN NI NN NI NI NN NN  
TAL-2: NI HD NI HD NI NN HD HD NG HD NI NG HD NG NN HD 
Restriction enzyme: BspCNI (www.neb.com/R0624) 
 
Synthesis of GoldyTALENs 
DNA fragments encoding engineered TALE repeat arrays were constructed using the 
Golden Gate TALEN and TAL Effector Kit 2.0 (Figure 15). 
(http://www.addgene.org/taleffector/goldengatev2)144. The destination vector used was 
pkT3TS-goldyTALEN with LacZ145. The higher active RVD NN was used to target 
guanine instead of the less active NK146 and NH147 RVDs. In the first Golden Gate 
reaction, TALE repeats 1-10 were synthesized into pFUS_A or pFUS_B vectors. Colony 
PCR was run, to verify proper insertion of RVDs, primers: pCR8_F1 and pCR8_R1 
(Appendix B). Correct plasmids were transformed into competent bacterial cells. 
 
In the second Golden Gate reaction, the correct TALE repeats were synthesized into a 
pFUS_B4 vector. The two TALE pFUS vectors and the last nucleotide in either pLR-NI, 
-HD, -NG, or -NN were combined in the final Golden Gate reaction into the expression 
vector pkT3TS-goldyTALEN145 (Figure 15). The circular GoldyTALEN constructs were 
linearized and turned into RNA using mMESSAGE mMachine® T3 Kit (Life 
Technology, Cat#AM1340).   
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Chapter 3: Results 
 
DPP6 Results 
 
Examination of Zebrafish DPP6 orthologous proteins 
Comparison of zebrafish gene sequences indicate there was a whole genome 
duplication, hundreds of years ago61, leading to two zebrafish orthologs of DPP6, dpp6a 
(chromosome 24, 63.40% identity)  and dpp6b (chromosome 2, 59.02% identity). 
Chromosomal gene arrangement is an indicator of evolutionary history; therefore, 
synteny was investigated for both paralogs using the zebrafish section of Synteny 
Database142,148. The dpp6a region maintains higher synteny (5 gene loci, Figure 3a) to 
human DPP6 chromosomal region than the dpp6b chromosomal region (3 gene loci, 
Figure 3). Expansion of the sliding gene window from 100 to 200 genes further 
demonstrates a closer relationship between human chromosome 7 and D. rerio 
chromosome 24 (data not shown). 
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Figure 3. Scaled synteny mapping of human DPP6 and D. rerio dpp6a, dpp6b. Zebrafish 
Synteny Database outputs demonstrate that Z) Human chromosome 7 (Hsa7, Green) and 
D. rerio chromosome 24 (Dre24, blue) have a closer evolutionary relationship, as they 
share five syntenic genes, while Zb) Hsa7 (green) and D. rerio chromosome 2 (Dre2, blue) 
share three syntenic genes. Orange lines connect the orthologs, and curved edges indicate 
directionality of the gene.   
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DPP6 ab41811 Antibody in zebrafish 
In order to ascertain concentration and localization of Dpp6 in D. rerio, two 
antibodies were tested: rabbit anti-DPP6 (ab41811) and rabbit anti-DPP6 (ab198506).  
 
 
 
Figure 4. DPP6 antibodies epitope alignment of human and zebrafish orthologs using 
Clustal Omega. Human DPP6 (NP_570629.2), Dpp6a (XP_009295542.1), Dpp6b 
(XP_005163346.1) and (A) abcam 41811 (human 765-865 (amino acids) (aa)). (B) 
abcam 198506 (human 450-550aa). Asterisk indicates perfectly conserved, colon 
indicates amino acids with different properties, but still slightly conserved, and a no 
annotation means amino acids in that positon are not conserved.   
 
 
 
Dpp6a is 810 amino acids (aa) long, and is expected to create a band on Western 
blots at 92.8 kDa. Dpp6b is 857aa long, and a band should be observed around 97.4 kDa. 
In mouse, DPP6 (abcam: ab41811) antibody forms a band around 100kDa149. Protein was 
extracted using two, different, buffers: RIPA buffer (ThermoFisher, Cat#89901) with 
protease inhibitor (PI) (ThermoFisher Scientific, Cat#78441B) (Figure 5A) extraction 
buffer with PI lane 1: 4 WT zebrafish eyes, lane 2: 3 WT zebrafish brains. In Figure 5A, 
protein bands were observed at 89.5 kDa, 55.1 kDa, 47.8 kDa and 39 kDa (lane 1), while 
in lane 2, bands are observed at 109.5 kDa, 84.2 kDa, 55.1 kDa, 46.8 kDa, 38.5 kDa and 
33.9 kDa. 
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In Figure 5B lane 1 (brain tissue) there are bands at: 90.6 kDa, 73.1 kDa, 58.9 
kDa, 55.6 kDa and 39.6 kDa. Lane 3 (eye tissue) bands are visible at: 120.3 kDa, 57.8 
kDa, 46.9 kDa, 40.8 kDa and 34.2 kDa. Lanes 2 and 4 are the acetylated-tubulin control, 
bands are observed at 49 kDa and 46.9 kDa respectively. 
 
 
 
 
 
Figure 5. DPP6 (ab41811) shows non-specific binding in adult WT zebrafish neuronal 
tissue. S1 fraction separated on a 7.5% SDS-PAGE gel. DPP6 (ab41811) 1:5000, rabbit 
(rb) anti-goat AP-conjugated (secondary) 1:5000. Protein extracted (A) with RIPA buffer 
and PI. Lane 1: 2 brains, lane b: 4 eyes, (B) with extraction buffer (Appendix C). Lane 1 
and 3: rb anti-DPP6 (ab41811) 1:500, Lanes 2 and 4: mouse (ms) anti-acetylated !- tubulin 
1:2000. 
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Specific binding was not observed with ab41811, as Western blots in mice had 
shown higher specificity of the antibody52,149. A second antibody was experimented with: 
DPP6 RabMAb® (abcam:198506). The same batch of protein was utilized for Figure 6B 
and the DPP6 RabMAb® Western blot. No bands were observed for either zebrafish 
brain or eye neuronal tissue (data not shown). 
PSMD12 Results 
 
Zebrafish and Human PSMD12 comparison 
Mutations in PSMD12 cause specific ASD behavioral phenotypes84; therefore, we 
propose that PSMD12 is not a critical component of all proteasomes, but is a specific 
regulatory component of neuronal proteasomes. Previous work by Thisse and coworkers 
demonstrated that psmd12 in zebrafish is expressed within the head region of embryonic 
zebrafish150; however, as this was a high throughput screen, detailed analysis of 
expression has not been performed. Therefore, our first goal was to describe Psmd12 
expression both temporally and spatially.  
BLAST alignments of human PSMD12 to the zebrafish genome identified a PSMD12 
ortholog. The protein exhibits 86.84% sequence identity (NCBI: AIC49518.1, 
AAI65732.1). PSMD12 amino acid sequences compared between yeast and human 
suggest high conservation throughout evolution; therefore, we propose a common 
function within the 26S proteasome. 
Synteny mapping using the zebrafish Synteny Database142,148 shows 30 paired genes 
between zebrafish psmd12 and human PSMD12. BLAST of zebrafish genomic sequences 
confirmed only one copy of psmd12 present (data not shown). 
 
 27 
 
 
 
 
 
 
 
Figure 6. A 50 gene-sliding window of human PSMD12 and zebrafish psmd12 show seven 
syntenic genes shared. Zebrafish Synteny Database outputs demonstrate that A) Human 
chromosome 17 (Hsa17, green) and D. rerio chromosome 6 (Dre6, blue) share seven 
syntenic genes, orange lines connect the orthologs, and curved edges indicate directionality 
of the gene.   
 
 
 
 
 
 
 28 
Specific PSMD12 Antibody for zebrafish 
In order to ascertain concentration and localization of psmd12 in D. rerio two antibodies, 
designed against human PSMD12, were tested: rabbit anti-PSMD12 (ab156604) and 
rabbit anti-PSMD12 (ab137932).  
 
 
 
 
 
Figure 7. PSMD12 antibody epitope alignments against human and zebrafish using Clustal 
Omega. Red amino acids show completely mismatched amino acids, and green show 
mismatched amino acids with similar properties. (A) NP_002807.1 (human PSMD12), 
NP_963872.1 (zebrafish Psmd12) and abcam 137932 (human 137-186aa). B) 
NP_002807.1, NP_963872.1 and abcam 156604 (human 276-304aa). 
 
 
 
 
PSMD12 ab156604 was designed against human PSMD12 (274-304aa). A Clustal 
Omega alignment of human, D. rerio and the ab156604 epitope shows, 89.66% match, D. 
rerio has a three amino acid differences: amino acid 277 tyrosine (Y) instead if a 
phenylalanine (F), 292 threonine (T) instead of a glycine (G) and 303 arginine (R) instead 
of a lysine (K).  
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PSMD12 ab137932 was designed against human PSMD12 (137-186aa). A Clustal 
Omega alignment of human, D. rerio and the ab137932 epitope shows, 90% match, D. 
rerio has five amino acid differences: aa 151 histidine (H) instead if a threonine (T), 156 
serine (S) instead of an asparagine (N), 164 alanine (A) instead of a serine (S), 184 lysine 
(K) instead of an arginine (R), and 183 alanine (A) instead of a valine (V). 
Western blots were run using neuronal protein extracted from either one, two, or 
three zebrafish with either extraction buffer or RIPA buffer and blotted with antibody 
ab155604 (Figure 8). Rabbit anti-goat conjugated AP was used as the secondary antibody 
at a concentration of 1:5000 (Appendix A). Zebrafish Psmd12 is 456aa long; therefore, 
we expected to observe a band in Western blots at 52.82 kDa. In figure 7A, bands are 
observed at 52 kDa, 50 kDa, 51 kDa and 50 kDa in lanes 1 through 4 respectively. 
However, unexpected bands were observed in all lanes at 115 kDa, 72 kDa (doublet 
band) and 38 kDa. In lane 2, there were four unexpected bands at 58.4 kDa, 41.2 kDa, 
33.8 kDa and 30 kDa. In lanes 3 and 4 there was one unexpected band each at 37.7 kDa 
and 59.3 kDa respectively. A more stringent buffer was used in order to break the bonds 
associating with our protein of interest. Decreasing the non-specific binding seen in 
Figure 8A. 
When the protein was extracted using RIPA buffer (Figure 8B) only one 
unexpected band was observed at 32 kDa in eye tissue and no unexpected bands were 
observed in brain tissue. The PSMD12 ab156604 antibody showed a specific band at 55 
kDa in eye tissue, and 54 kDa in brain tissue.  
The PSMD12 ab137932 antibody did not show remarkable bands. There was a 
faint band observed around 50 kDa. Despite larger amounts of protein isolated from one, 
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two or three adult WT zebrafish neuronal tissue and an increased primary antibody 
concentration of 1:250, no notable bands were observed (data not shown). 
 
 
 
 
 
 
Figure 8. PSMD12 ab156604 antibody shows further specificity when proteins are 
extracted with RIPA buffer. WT zebrafish neuronal tissue S1 fractions run in 7.5% SDS-
PAGE. PSMD12 (ab156604) 1:500, AP-conjugated goat anti-rabbit (Jackson Labs 111-
055-003) 1:2000. Bands observed at expected size 52 kDa. (A) Protein extracted with 
standard extraction buffer (Appendix C) and PI. Lane 1: 6 eyes, lane 2: 3 brains, lane 3: 4 
eyes, and Lane 4: 2 brains. (B) RIPA buffer with PI. Lane 1: 3 brains, lane 2: 2 brains, 
lane 3: 1 brain, lane 4: 6 eyes, lane 5: 4 eyes and lane 6: 2 eyes. 
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Constructs to elucidate the function of PSMD12 
PSMD12 and PSMD14 interact in the regulatory lid of the proteasome inhibiting 
de-ubiquitination of proteins151 by obstructing the PSMD14 active site82. Unfortunately, 
PSMD12’s function in vertebrates has not been examined, and specific roles for PSMD12 
within the nervous system were only recently suggested due to its association with ASD. 
Proteasome dysfunction in other neurologic diseases leads to protein aggregations, and 
cell death; therefore, we hypothesize that PSMD12 will alter cell viability of specific 
neuron classes that have previously been observed to be involved in ASD. Our long-term 
goal will be to quantify the viability of developing GABAergic and serotonergic neurons 
in the developing zebrafish.   
In order to determine the function of PSMD12, PSMD12 was cloned into an 
expression vector in order to overexpress or rescue a KO, while MO and TALENs were 
created to knockdown or KO the protein function. 
 
Full length PSMD12 cloned in an expression vector 
The full length, zebrafish, PSMD12 gene was cloned in to a Promega pGEM®-T 
vector (Cat#A362A). The construct was transformed into JM109 bacterial cells, and 
DNA harvested using Qiagen minipreps (Cat#27106). The clones were verified using 
Sanger sequencing (Eurofins SimpleSeq) using the T7 and SP6 primers, and sequences 
verified using NCBI gene bank (ID: BC165732.1).  
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TALENs 
TALEN Design and Screening 
The goal of the TALEN is to disrupt the protein sequence enough to impair its 
translation. A frameshift mutation from the TALEN may cause a noticeable phenotype. 
Specific sequences in zebrafish Psmd12 were targeted due to their high conservation 
from zebrafish to human (Figure 9).  
 
 
 
 
 
Figure 9. Highly conserved regions targeted in zebrafish Psmd12. Top image is of 11 exons 
in zebrafish psmd12 with TALEN targeted regions in purple. Summation of conservation 
regions of PSMD12 protein from Saccharomyces cerevisae (S. cerevisae). to H. sapiens. 
PSMD12 homologs compared against seven species and the amount of conservation of 
each amino acid was analyzed, depicted in a bar graph from CLC Workbench. Purple 
arrows indicate where the TALEN will bind to DNA.  
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There was a high amount of variability in the inclusion of exon 1 and exon 2. We 
wanted to KO regions of the chromosome that were conserved from human to yeast. 
Therefore, we targeted exon 3, to ensure we hit all isoforms. 
Gene models show variably within exon 1 and 2; therefore, exon 3 was targeted to 
remove all isoforms of psmd12. Two TALENs were created for exon 3, and one for exon 
6. TALENs in exon 3 should disrupt the protein early; therefore, we are hoping for a 
complete null phenotype. TALEN 3 is targeted to exon 6. This is to KO a conserved 
region in exon 6 (I-L-E) that is conserved from humans all the way to S. cerevisae 
(Figure 9).  
 
Genomic screening for psmd12 mutation  
In order to genotype mutations caused by TALEN 1 (TAL1), TALEN 2 (TAL2) 
and TALEN 3 (TAL3), restriction enzymes sites (AlwI, BbvI and BspCNI respectively) 
were designed within the TALEN spacer region, so that when deleted these sites would 
be lost. TAL 1 and 2 are designed within exon 3; therefore, primers were designed 
against genomic DNA to yield a band at 1,000 bp, while primers flanking will produce a 
band at 1,189 bp (Figure 10A). In wild-type animals, AlwI will cut genomic DNA and 2 
bands will be observed at 668 bp and 399 bp, BbvI will cut producing two bands at 668 
bp and 500 bp; and BspCNI will cut producing three bands at 800 bp, 400 bp and 168 bp. 
This allows for rapid and cost effective identification of mutation through loss of 
restriction sites and a long-term solution for genotyping. 
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Figure 10. TALEN genotyping assay. 1% agarose gel with 5% EtBr. The top image shows 
the 11 exons in zebrafish psmd12 in green are the PCR primer targeting sites. (A) PCR of 
genomic DNA for either exon 3 (target sites for TAL1 and TAL2), or exon 6 (Target site 
for TAL3) (B) Restriction enzyme digests of the PCR products in (B) AlwI is utilized for 
TAL1, BbvI for TAL2, and BspCNI for TAL3. Black arrows indicate the 3 bands when 
PCR product is digested with BspCNI. 
 
 
 
 
Creation of TALENs targeting Exon 3 and Exon 6 of psmd12 
Colony PCR confirmed successful insertion of RVDs into either pFUS_A or 
pFUS_B vectors (Figure 11). PCR primers: pCR8_F1and pCR8_R1 (Appendix B). 
Successful pFUS_A inserts will form a band around 1200 bp and pFUS_B will form a 
band around 750 bp. We expected to see the “laddering” effect because primers used 
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should bind to each individual RVD. Incorrect insertion of RVDs will show a single, 
solid band around 250 bp. 
 
 
 
 
 
 
Figure 11. Colony PCR of TALEN pFUS_A and pFUS_B array constructs. 1% agarose 
gel with 5% ethidium bromide (EtBr). pFUS_A constructs form a band around 1200 bp, 
pFUS_B constructs band around 750 bp and both produce a ‘laddering’ effect below band. 
(A) Lane 1: TAL 1-1, 10 RVDs in pFUS_A plasmid. Lane 2:  TAL1-1, 5 RVDs in pFUS_B 
plasmid. Lane 3: TAL1-2, 10 RVDs in pFUS_A plasmid. Lane 4:  TAL 1-2, 7 RVDs in 
pFUS_B plasmid. (B) Lane 1: TAL 2-1, 10 RVDs in pFUS_A plasmid. Lane 2: TAL2-1, 
6 RVDs in pFUS_B plasmid. Lane 3: TAL2-2, 10 RVDs in pFUS_A plasmid. Lane 4: TAL 
2-2, 6 RVDs in pFUS_B plasmid. (C) Lane 1: TAL 3-1, 10 RVDs in pFUS_A plasmid. 
Lane 2: TAL3-1, 7 RVDs in pFUSB plasmid. Lane 3: TAL3-2, 10 RVDs in pFUS_A 
plasmid. Lane 4: TAL 3-2, 6 RVDs in pFUS_B plasmid.  
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Creation of full TALEN constructs in pKT3Ts-goldyTALEN 
In order to identify correct assembly of pFUS_A, pFUS_B, pLR-X and pKT3Ts-
goldyTALEN (Golden Gate reaction two) (Figure 15) colony PCR was run using 
primers: TAL_F1 and TAL_R2 (Appendix B).  
 Successful assembly of individual TALENs will form a single band just below 
2,000 bp with “laddering” effect below. The “laddering” effect is observed because 
primers are expected to bind to each RVD. Failed assembly will show two bands: one 
between 3,000-2,000 bp and the other around 650 bp, with no “laddering”. All TALENs 
in Figure 12 were sequence verified via Sanger sequencing (Eurofins SimpleSeq), 
primers used for sequencing: TAL_Seq_5-1 and TAL_R3 (Appendix B). 
 
 
 
 
Figure 12. Colony PCR of TALEN products successfully inserted into pKT3TS-
goldyTALEN. 1% agarose gel with 5% EtBr. Primers: TAL_F1 and TAL_R2. (A) TALEN 
1: Lanes 1-3: TAL1-1 (upstream), Lanes 4+5: TAL1-2 (downstream). (B) TALEN 2: Lanes 
1+2: TAL2-1 (upstream), lanes3-6: TAL2-2 (downstream). (C) TALEN 3: Lane 1: TAL3-
1 (upstream), Lane 2+3: TAL3-2 (downstream).  
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MO Results 
Knockdown of PSMD12 ATG 
Bands were observed in all injected and uninjected conditions. The amount of 
Psmd12 observed differed in each condition. In Figure 13D, a second band was observed 
around 62 kDa in all conditions except in 10.5 ng. In Figure 13E, protein was extracted 
from 2 dpf embryos and a doublet band was observed, around 62 kDa, in both PSMD12 
ATG MO and the mismatch injection. GAPDH was used as a loading control in all blots.  
 
 
 
Figure 13. Western blots of PSMD12 ATG MO injected embryos. S1 fraction run in a 
7.5% SDS-PAGE. Primary antibody: PSMD12 (ab156604) used at concentration 1:500, 
and GAPDH (loading control) used at a concentration of 1:3000.  Secondary antibody: 
rabbit anti-goat AP conjugated used at a concentration of 1:5000. Bands visualized via AP 
buffer (Appendix C), 1% BCIP and 1.5% NBT. (A-D) 3dpf embryos (E) 2dpf embryos. 
UC: uninjected control (wild-type), C1: collection one, C2: collection two.   
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Figure 14. Average Psmd12 level and viability of MO injected zebrafish embryos. 
Quantified protein was normalized to GAPDH control and normalized a second time to the 
mismatch (MS) protein levels of PSMD12. Viability was determined by calculating the 
difference of the total number of embryo injected and total number of surviving embryos 
one day after injection. One-way ANOVA: F(2,9)=32.8, P=7.35x10-5. Tukey HSD shows 
MS to 3 ng, (p=0.001), mismatch (MS) to 6 ng, (p=0.001) and 3 ng to 6 ng (p=.475). ** 
indicates a p<0.001. 
 
 
 
 
Protein was normalized to GAPDH and normalized a second time to the mismatch 
levels of Psmd12. Data was scored blindly. We see a 52% KD of Psmd12 in 6 ng, MS to 
3ng=0.001, MS to 6ng, p=0.001, and 3ng to 6ng, p=.475. A minimum of three replicates 
were run per condition. We see a significant reduction in protein (F(2,9)=32.8, 
P=7.35x10-5) as determined by a one way ANOVA, a Tukey post-hoc test demonstrates 
significant KD at both 3 ng (p=0.01) and 6 ng (p=0.01). No significant difference was 
seen between 3 and 6 ng KD (p=0.475).  
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Chapter 4 Discussion 
DPP6 Discussion 
 
Human DPP6 and Zebrafish orthologs compared  
 
There are many lines of evidence that suggest DPP6 may play a role in the 
etiology of ASD: 1) Mutations in DPP6 have been observed in autistic patients, 2) DPP6 
has an altered expression pattern in post mortem brains of autistic individuals versus 
neuro-typical controls29,42,152 , 3) DPP6 and A2BP1 (another ASD candidate gene) are co-
expressed in a dataset that contains over 14,000 different microarrays (unpublished data 
Dr. Brent Bill), and 4) the work of Bowers and Konopka demonstrates A2BP1 and DPP6 
are both co-regulated by FOXP2, a transcription factor with known roles in speech and 
ASD153. Given the defined expression pattern for DPP6 in mammals, we hypothesize 
expression of dpp6 is critical for its function, and it will be important to understand its 
functional role in neuro-typical brain development, and how that differs in ASD. 
In adult zebrafish, dpp6b is expressed in brain regions similar to the expression of 
murine Dpp6, specifically within the habenula, cerebellum and olfactory bulb154,155. 
Additionally, IHC of adult zebrafish identified expression of Dpp6 in the fasciculus 
retroflexus (axons of habenula) and areas associated with the optic and auditory sense 
modalities (unpublished data, Dr. Bill) (Figure 2). This data supports the use of zebrafish 
as a tool to explore Dpp6, and may highlight new neuronal systems. One common 
symptom of ASD is altered sensitivities to environmental stimuli, such as fluorescent 
versus incandescent lights, hypersensitivity to sound and touch. This suggests a need to 
look at these modalities behaviorally in zebrafish, as pharmaceuticals that could modulate 
sensitivities would be quite a powerful tool for ASD treatment. 
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In order to determine the suitability of the zebrafish homologs for these studies. 
Human DPP6 resides on chromosome 7, zebrafish dpp6a resides on chromosome 2 and 
dpp6b resides on chromosome 24. Using Clustal Omega Dpp6a, Dpp6b and human DPP6 
protein sequences were compared via a percent identity matrix. The results support our 
synteny mapping data by showing Dpp6a is 4.38% more closely related to DPP6. 
Moreover, at the nucleotide level, Dpp6a is more allied to DPP6 than Dpp6b.  
Dpp6a is located on chromosome 24 and has five genes within 0.94 mega bases 
(Mb) of DNA that is syngeneic with DPP6. Dpp6b is located on chromosome 2 with 
three number of genes within 0.8 Mb of DNA that is syntenic with DPP6. Important cis 
regulatory transcription factors usually fall within 10 kb of the beginning of the gene, 
although regional regulators can be much further away. The conservation of these 
regulatory factors could provide valuable information regarding the expression of DPP6.   
 
DPP6 expression in zebrafish  
We hypothesized the Western blot utilizing the DPP6 ab41811 antibody would 
bind specifically to Dpp6 protein in zebrafish. IHC showed staining of olfactory regions 
and the habenula in mouse and zebrafish, and in situ hybridization in the fish conformed 
localization of the mRNA in these locations. Dpp6 expression labeled by ab41811 
showed staining of the axons in zebrafish (Figure 5). Expression in axons was widespread 
throughout the brain, so to determine the specificity of the antibody for Dpp6 Western 
blotting was performed. A single band or a double band between 90 kDa and 97 kDa was 
expected; however, the presence of additional, unanticipated, bands in Figure 5 suggests 
possible cross-reactions, protein degradation or protein complexes due to insufficient 
denaturation. Other commercially available antibodies and different extraction buffers 
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were assessed while working with zebrafish Dpp6 to determine if the additional bands 
were due to technique or due to non-specific binding. Based in our current data, this 
binding is non-specific. 
The epitope alignment of ab198506 showed a 75.33% and 70.95% identity with 
Dpp6a and Dpp6b respectively. However, the epitope was in the middle of the protein, 
human amino acids 450-550, which may be a reason why no bands were observed. In 
order to verify a sufficient amount of protein transferred to the PVDF membrane (data 
not shown) total protein was observed with Ponceau S (Appendix C). The fact that there 
were no visible bands was not due to a lack of protein in the membrane. Since the same 
protein worked in previous Western blots, we can also conclude it was not due to an 
extraction issue. In titrating the antibody, a concentration up to 1:250 was used, much 
higher than most Western blotting protocols. Taken together this antibody is not capable 
of recognizing zebrafish Dpp6.  
Multiple bands were observed in Western blots with both extraction and RIPA 
buffer extracted protein blotting with antibody ab41811. No bands were observed in 
Western blots with RIPA buffer extracted protein blotted with antibody ab198506. We 
can conclude that Dpp6 is capable of being extracted using mild conditions, even though 
it is a transmembrane protein156. Dpp6 is expressed in zebrafish neuronal proteins and is 
not capable of being recognized, in a specific manner, with DPP6 antibody ab41811 or 
ab198506.  
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Future Studies for DPP6 
Based on conservation, expression, and the ability of the human antibody to cross 
react with the zebrafish dpp6, we proposed the zebrafish homologs will be functionally 
similar; therefore, a good tool for future studies.   
Sequencing of bands from Figure 5 to determine their identity. Creation or 
discovery of a more specific antibody would helpful. Places where we have seen overlap 
in the in situ and IHC are places we would like to look (Figure 2). 
 
PSMD12 Discussion 
 
Zebrafish and Human PSMD12 comparison 
 
Alignment of human and zebrafish Psmd12 protein showed an 86.84% identity 
match. psmd12 is located on chromosome 6 with seven numbers of genes within 1.74 Mb 
of DNA syngeneic with human PSMD12. Just like in DPP6, the conservation of these 
regulatory factors could provide valuable information as to the expression of Psmd12 due 
to the location of regulatory transcription factors. 
 
Specific PSMD12 Antibody for zebrafish 
 
From this data it is clear PSMD12 ab156604 is the better antibody for zebrafish 
neuronal Psmd12. The alignment of the antibody epitope against zebrafish Psmd12 
showed only a 3aa difference (Figure 7). The antibody showed specific binding when 
proteins were extracted using a more stringent extraction buffer, RIPA (Figure 8). 
Therefore, harsher extraction conditions are recommended when utilizing this antibody in 
zebrafish.  
 
 43 
Chromosomal editing of zebrafish PSMD12 
 
Three different chromosomal editing tools were created to help elucidate Psmd12 
function and location in zebrafish. An overexpression vector, three TALENs and three 
MO. 
Zebrafish psmd12 was cloned into an expression vector and it can be used to 
overexpress Psmd12 in zebrafish. Utilizing this may allow us to understand what happens 
when Psmd12 is functionally redundant, and it can help rescue a phenotype if a KO 
mutation transpires to be detrimental157.    
The three TALENs created can be used individually or in combination with the 
others. Therefore, major mutations can be introduced into Psmd12. Multiple TALENs 
have been successfully used in combination to removed multiple exons in zebrafish158. 
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Figure 15. Golden Gate reactions. Using type IIS restriction endonucleases (BsaI and 
Esp3I) plasmids are digested and ligated together in a specific sequential manner. Step 1: 
Ten or more module plasmids containing RVDs ligated into array plasmids (p_FUS_A or 
p_FUS_B). Step 2: pFUS_A, pFUS_B, last repeat plasmid and pkT3Ts-goldy TALEN 
are digested and ligated in the destination vector (pkT3Ts-goldyTALEN). RVD: Random 
repeat variable diresidue, Tet: tetracycline, Spec50: spectinomycin50, Kan: kanamycin.  
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Correct colony PCR samples were transformed into One Shot® Mach1™ and 
DH5⍺ chemically competent bacterial cells. DH5⍺ bacterial cells were used to transform 
pFUS_B, however, we found when transforming the pFUS_A constructs the One Shot® 
Mach1™ yielded a higher success rate. One Shot® Mach1™ cells have a transformation 
efficiency > 1x109. DH5⍺ cells have a transformation efficiency > 1x106. The pFUS_A 
constructs were all 10 RVDs in length, and the pFUS_B were anywhere between 5 to 7. 
Therefore, we think due to the larger size of the pFUS_A constructs the higher efficiency 
bacterial cells were necessary.  
The DH5⍺ cells worked extremely well with the pFUS_B constructs. We had a 
success rate of about 70-80%. The success rate of pFUS_A constructs with DH5⍺ cells 
was 0%, and it was about 25% with the One Shot® Mach1™ cells. However, DH5⍺ cells 
yielded the only successful transformations during Golden Gate reaction two (Figure 15).  
 
Morpholinos 
Exon 3 was targeted because when looking at the protein alignment map, (Figure 
9) you start to see conservation of sequence through the species around exon 3. IHC, of !-acetylated tubulin, on 2 dpf MO injected embryos showed no noticeable differences in 
sensory neurons (data not shown). However, Küry and colleagues (2017) showed axon 
guidance defects and decreased optic tecta size with the mosaic CRISPR85. Therefore, we 
expected to see phenotypic differences if we look at deep neurons vs. superficial sensory 
neurons. If neuroanatomical and behavioral phenotypes were observed the animals would 
have been assessed and it would provide information for the transgenic lines used for 
TALEN outcrosses.   
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Future studies for PSMD12 
 
Quantification will be performed within transgenic zebrafish lines that express 
fluorescent molecules within specific neurons: Gad1-1:mCherry (hindbrain and spinal 
GABAergic neurons), DLX5a-6a:GFP (forebrain and midbrain GABAergic neurons), 
and Th2:GFP (brain and gut serotonergic neurons). As with other disorders, we expect 
protein aggregations will precede cell death in the neurons that lack Psmd12. 
Alternatively, if cell death is not observed, further analyses of neuron morphology and 
function will be performed. 
In order to elucidate a phenotype of our MO and TALENs, IHC using similar 
procedures Küry and colleagues (2017) should be done. Therefore, in the future deep 
neurons should be targeted and embryos 3 dpf should be used. Studies like these will add 
in unraveling the role PSMD12 plays when it is KD. From this we can begin to 
understand how proteasome remolding caused by PSMD12 KD can lead to a 
neurodevelopmental syndrome.  
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Appendix A: Antibodies 
Primary Antibodies:  
abcam: Anti-DPP6 antibody - Catalytic domain 
rabbit anti-DPP6 (ab41811)  
WB: 1:500 
 
abcam: Anti-DPP6 antibody 
RabMAb® rabbit anti-DPP6 (ab198506): monoclonal 
WB: 1:1000 
 
abcam: Anti-26S proteasome non-ATPase regulatory subunit 12 antibody 
rabbit anti-PSMD12 (ab156604): polyclonal 
WB: 1:500 
 
abcam: Anti-26S proteasome non-ATPase regulatory subunit 12 antibody 
rabbit anti-PSMD12 (ab137932): polyclonal 
WB: 1:250-1:500 
 
Sigma Aldrich: Product #: T6793 
mouse anti-acetylated α-tubulin: monoclonal anti-tubulin, acetylated antibody produced 
in mouse 
WB: 1:2000 
 
abcam: Anti-GAPDH antibody  
rabbit anti-GAPDH (ab209856): polyclonal to GAPDH Predicted 37 kDa 
WB: 1:500-1:3000 
IHC: 1:100-1:1000 
 
 
Secondary Antibodies:  
Alkaline Phosphatase AffiniPure Goat Anti-Rabbit IgG (H+L) (Jackson, Cat#111-055-003) 
WB: 1:5000 
 
Alkaline Phosphatase AffiniPure Goat Anti-Rabbit IgG (H+L) (Jackson, Cat#112-055-175) 
WB: 1:5000 
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Appendix B: Primers 
PSMD12 Primers. 
 
Primer Name Sequence 5’-3’ OD nmol ug Len MW Tm 
gPSMD12-373F CGTGCTCATATTTCGTAGTTTACAT 15.1 65.6 499.7 25 7613.1 59.7 
gPSMD12-1392R TCAAGAGCACAAGAGAGATTCC 14.7 63.1 426.4 22 6761.5 60.8 
gPSMD12-3295F CTTGGGCTCTCCTACTCAATTT 14.3 75.3 499.1 22 6627.4 60.8 
gPSMD12-Exon7R CTTCCAGAATACAAGGAGTGTCATA 13.8 53.9 413.9 25 7674.1 61.3 
 
 
Morpholino Primers. 
 
Name Sequence MW Molar Abs. Weight OD Holdback 
PSMD12ATG CATCAGACATTGTTGCAGCTAGTA 8128 252230 2.44 75.67 300 nmol 
PSMD12E3SA GACACCATATCCGAAGCCTGGAAA 8116 255990 2.43 76.80 300 nmol 
PSMD125p GCAGCGAATGTGACAACTACGATC 8147 254360 2.44 76.31 300 nmol 
PSMD12ATGms CATCCGACGAAGTTGCACCTCGTA 8074 246550 2.42 73.97 300 nmol 
 
 
TALEN primers. 
 
pCR8_F1: TTGATGCCTGGCAGTTCCCT 
pCR8_R1: CGAACCGAACAGGCTTATGT 
TAL_F1: TTGGCGTCGGCAAACAGTGG  
TAL_R2: GGCGACGAGGTGGTCGTTGG 
TAL_Seq_5-1: CATCGCGCAATGCACTGAC (use this for sequencing in place of TAL_F1)  
TAL_R3: GGCTCAGCTGGGCCACAATG 
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Appendix C: Solutions 
 
Protein Extraction Buffer 
 
50 mM Tris HCl (1M) pH8 
0.1% NP-40 
0.05% Triton X-100 
150 mM NaCl (5M) 
 
Recipe for 500 mL:    
25mL Tris HCl 
500ul NP-40 
250ul Triton-X 
15mL NaCl (5M)  
Nanopure water to a final volume of 500 mL 
 
6X SDS Loading Buffer 
 
10% SDS (sodium dodecyl sulfate) 
30% glycerol 
375 mM Tris-HCl (pH 6.8) 
0.2% Bromphenol Blue 
 
Recipe for 15 mL:    
1g of 10% SDS 
3mL of 100% glycerol 
7mL of .5 M Tris-HCl, pH 6.8 
1.2mg of Bromophenol Blue 
Nanopure water to a final volume of 15 mL 
10X Tris-Glycine Running Buffer 
 
25 mM Tris-base 
250 mM glycine 
0.1% SDS 
pH 8.3 
 
Recipe for 1L: 
30.3g Tris-base  
144g glycine 
10.08g SDS 
Distilled water to a final volume of 1L 
10X Tris-buffered saline (TBS) 
 
20mM Tris-base pH 7.5 
150mM NaCl 
 
 
 
Recipe for 1L: 
24g Tris-base 
88g NaCl 
Dissolve in 900mL nanopure water  
pH to 7.6 
Nanopure water to a final volume of 1L 
 
Tris-buffered saline, 0.1% Tween-20 (TBST) 
 
20mM Tris-base pH 7.5 
150mM NaCl 
0.1% Tween 20 
 
Recipe for 1L: 
100mL of TBS 10X 
900mL distilled water 
1mL Tween 20 
Nanopure water to a final volume of 1L 
Ponceau S Stain 
 
0.2% Ponceau S 
5% glacial acetic acid 
Recipe for 50 mL: 
.5g Ponceau S (FisherScientific, Cat#6226-79-5) 
Dissolve in 2.5 mL glacial acetic acid 
47.5mL nanopure water 
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Appendix C (Continued) 
 
5% Milk Block 
2.5g powder milk 
50mL TBST 
 
Bjerrum Schafer Nielsen (BSN) Transfer Buffer 
25 mM Tris-base 
190 mM glycine 
20% methanol 
 
Recipe for 1L: 
5.82g Tris-base 
2.93g glycine 
Dissolve in 500mL of nanopure water 
200mL methanol 
Nanopure water to a final volume of 1L 
Tris-acetate-EDTA (TAE) Buffer 
Working solution 1X:  
40 mM Tris (pH 7.6) 
20 mM acetic acid 
1 mM EDTA 
 
Recipe for 1L: 
4.82g Tris-base 
11.42mL glacial acetic acid 
2mL 0.5 M EDTA (pH 8.0) 
Nanopure water to a final volume of 1L 
 
Stock solution 50X 
2 M Tris (pH 7.6) 
.100 M acetic acid 
50 mM EDTA 
 
Recipe for 1L  
242g Tris-base 
571.1mL glacial acetic acid 
100mL 0.5M EDTA (pH 8.0) 
Nanopure water to a final volume of 1L 
Nitro blue tetrazolium chloride (NBT) 
1ml 70% DMF (Dimethylformamide) 
30mg NBT 
 
5-Bromo-4-chloro-3-indolyl phosphate (BCIP) 
15mg BCIP 
1mL of DMF 
 
Alkaline Phosphate (AP) Buffer 
3.5 mM MgCl2 
.1 M Tris-base 
Recipe for 500mL: 
165mg MgCl2 
6.05g Tris-base 
pH 9.5 
Nanopure water to a final volume of 500mL  
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Appendix C (Continued) 
 
Phosphate Buffered Saline (PBS) 
Stock solution (20X) 
2.7 M NaCl  
.05 M KCl  
.2 M Na2HPO4  
.036 M KH2PO4 
 
Recipe for 1L: 
Stock solution (20X) 
160g NaCl 
4g KCl 
2.88g Na2HPO4 
4g KH2PO4 
pH to 7.4  
Distilled water to a final volume of 1L 
 
Working solution (1X) 
137 mM NaCl 
2.7 mM KCl 
10 mM Na2HPO4 
1.8 mM KH2PO4 
 
Recipe for 1L: 
Working solution (1X) 
8g NaCl 
0.2g KCl 
1.44g Na2HPO4 
.24g KH2PO4 
pH to 7.4  
Distilled water to a final volume of 1L  
 
Phosphate Buffered Saline 0.1% Triton X-100 (PBST) 
1X PBS 
0.1% Triton X-100 
 
Immunohistochemistry Blocking Solution 
1X PBST 
1% DMSO 
1% Normal goat serum 
1% BSA 
 
LB+Agar Plates (25 plates) 
500mL Di-water 
12.5g LB (BD, Cat#244620) 
9.38g Agar 
Autoclave 
 
Antibiotic working concentrations:  
Tetracycline (10 ug/mL) 
Kanamycin (50 ug/mL) 
Ampicillin (100 ug/ml) 
Spectinomycin 50 (50 ug/mL)  
 
